skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Results 1 2 3 4 5 next page
Refined by: Journal Title: Journal Of Clinical Oncology remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients
Material Type:
Article
Add to My Research

10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1000-1000 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.31.15_suppl.1000

Full text available

2
13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia
Material Type:
Article
Add to My Research

13-cis-Retinoic acid does not increase the true remission rate and the duration of true remission (induced by cytotoxic chemotherapy) in patients with chronic phase chronic myelogenous leukemia

Journal of clinical oncology, 1985-04, Vol.3 (4), p.473-476 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.1985.3.4.473 ;PMID: 3856630

Digital Resources/Online E-Resources

3
17-year incidence trends of anal squamous cell carcinoma
Material Type:
Article
Add to My Research

17-year incidence trends of anal squamous cell carcinoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4058-4058 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2020.38.15_suppl.4058

Full text available

4
177 Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting
Material Type:
Article
Add to My Research

177 Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16249-e16249 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.16_suppl.e16249

Digital Resources/Online E-Resources

5
20-year incidence trends of anal squamous cell carcinoma
Material Type:
Article
Add to My Research

20-year incidence trends of anal squamous cell carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15503-e15503 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.16_suppl.e15503

Digital Resources/Online E-Resources

6
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
Material Type:
Article
Add to My Research

2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3187-3205 [Peer Reviewed Journal]

2006 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2006.06.4451 ;PMID: 16682719

Full text available

7
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)
Material Type:
Article
Add to My Research

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC)

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA506-LBA506 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.17_suppl.LBA506

Digital Resources/Online E-Resources

8
30-day readmission among gastrointestinal cancer patients in Texas
Material Type:
Article
Add to My Research

30-day readmission among gastrointestinal cancer patients in Texas

Journal of clinical oncology, 2013-11, Vol.31 (31_suppl), p.121-121 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2013.31.31_suppl.121

Full text available

9
30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa)
Material Type:
Article
Add to My Research

30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e16597-e16597 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2019.37.15_suppl.e16597

Full text available

10
300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?
Material Type:
Article
Add to My Research

300% increase rate in juvenile cancer cases unrelated to AIDS: Is it real?

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e17535-e17535 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2009.27.15_suppl.e17535

Full text available

11
5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care
Material Type:
Article
Add to My Research

5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.39-39 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2020.38.6_suppl.39

Full text available

12
5 x 5 Gy and consolidation chemotherapy vs long-course preoperative chemoradiation for locally advanced rectal cancer: An interim analysis of a randomized phase III study
Material Type:
Article
Add to My Research

5 x 5 Gy and consolidation chemotherapy vs long-course preoperative chemoradiation for locally advanced rectal cancer: An interim analysis of a randomized phase III study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15006-e15006 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2017.35.15_suppl.e15006

Full text available

13
5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study
Material Type:
Article
Add to My Research

5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1118-1126 [Peer Reviewed Journal]

1999 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.1999.17.4.1118 ;PMID: 10561169

Digital Resources/Online E-Resources

14
5-year survival following radiotherapy in anal cancer audit in a single center
Material Type:
Article
Add to My Research

5-year survival following radiotherapy in anal cancer audit in a single center

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e15070-e15070 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2019.37.15_suppl.e15070

Full text available

15
5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: Phase II study results
Material Type:
Article
Add to My Research

5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: Phase II study results

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.3599-3599 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2006.24.18_suppl.3599

Full text available

16
89 Zirconium-labelled girentuximab ( 89 Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma
Material Type:
Article
Add to My Research

89 Zirconium-labelled girentuximab ( 89 Zr-TLX250) PET in patients with urothelial cancer (ZiPUP): A phase I trial of a novel staging modality for urothelial carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4609-TPS4609 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2022.40.16_suppl.TPS4609

Full text available

17
89 Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX
Material Type:
Article
Add to My Research

89 Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS738-TPS738 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2023.41.6_suppl.TPS738

Full text available

18
90 Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Material Type:
Article
Add to My Research

90 Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1977-1983 [Peer Reviewed Journal]

ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400

Full text available

19
90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial
Material Type:
Article
Add to My Research

90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1977-1983 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400 ;PMID: 23547079

Full text available

20
90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial
Material Type:
Article
Add to My Research

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1977 [Peer Reviewed Journal]

EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.45.6400 ;PMID: 23547079

Full text available

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 1990  (119)
  2. 1990 To 1997  (268)
  3. 1998 To 2005  (608)
  4. 2006 To 2014  (3,381)
  5. After 2014  (5,402)
  6. More options open sub menu

Language 

  1. English  (9,776)
  2. Japanese  (645)
  3. Russian  (18)
  4. Norwegian  (4)
  5. More options open sub menu

Searching Remote Databases, Please Wait